Risk factors of osteopenia in HIV-infected women: No role of antiretroviral therapy

Maturitas

Volumn 65, Issue 1, 2010, Pages 51-54

  Libois, A ^a   Clumeck, N ^a   Kabeya, K ^a   Gerard, M ^a   De Wit, S ^a   Poll, B ^a   Tondeur, M ^a   Rozenberg, Serge ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

HAART; HIV; Osteopenia; Women

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AFRICA; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOPENIA; OSTEOPOROSIS; PREMENOPAUSE; PREVALENCE; RISK FACTOR; TREATMENT DURATION;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BELGIUM; BODY MASS INDEX; BONE DISEASES, METABOLIC; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LOGISTIC MODELS; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; WOMEN'S HEALTH; YOUNG ADULT;

EID: 72149117362     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.10.009     Document Type: Article

References (13)

1. Knobel H., Guelar A., Vallecillo G., Noqués X., and Diez A. Osteopenia in HIV-infected patients. Is it the disease or is it the treatment. AIDS 15 6 (2001) 807-808
2. Amarosa V., and Tebas P. Bone disease and HIV infection. Clin Infect Dis 42 (2006) 108-114
3. Paton N.I., Macallan D.C., Griffin G.E., and Pazianas M. Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int 61 (1997) 30-32
4. Bruera D., Luna N., David D.O., Bergoglio L.M., and Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17 (2003) 1917-1923
5. Tebas P., Powderly W.G., Claxton S., et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14 (2000) F63-F67
6. Mondy K., Yarasheski K., Powderly W.G., et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36 (2003) 482-490
7. Nolan D., Upton R., McKinnon E., et al. Stable or increasing BMD in HIV-infected patients treated with nelfinavir or indinavir. AIDS 15 (2001) 1275-1280
8. Yin M., Dobkin J., Brudnex K., et al. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int 16 11 (2005) 1345-1352
9. Arnsten J.H., Freeman R., Howard A.A., et al. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis 42 (2006) 1014-1020
10. Dolan S.E., Huang J.S., Killilea K.M., et al. Reduced bone density in HIV-infected women. AIDS 18 (2004) 475-483
11. Fausto A., Bongiovanni M., Cicconi P., et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone 38 6 (2006) 893-897
12. Gallant J.E., Staszewski S., Pozniak A., et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients. JAMA 292 2 (2004) 191-201
13. Looker A., Wahner H., Dunn W., et al. Updated data on proximal femur bone mineral levels of U.S. adults. Osteoporosis Int 8 (1998) 468-489